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Opinion paragraph 
 
Anaplastic oligodendroglial tumors have gained increasing interest with the emerging role of 
molecular markers and systemic chemotherapy during the last years. The long-term results of 
two landmark trials, RTOG 9402 and EORTC 26961, have resulted in a reconsideration of the 
appropriate therapeutic approaches for patients with these tumors. Both trials indicate that 
patients whose tumors harbor a 1p/19q co-deletion benefit particularly from the addition of 
procarbazine/lomustine(CCNU)/vincristine (PCV) chemotherapy to radiation therapy (RT). 
The median survival of patients with co-deleted tumors treated within the RTOG trial with 
PCV before irradiation was 14.7 years compared to 7.3 years of patients who received RT 
alone. Median overall survival has not been reached in the RT plus PCV arm of the EORTC 
trial but a similar difference can be anticipated after a follow-up of more than 12 years. In 
contrast, no such benefit was observed for patients with tumors lacking 1p/19q co-deletion. 
Outside clinical trials, patients with anaplastic oligodendroglial tumors and 1p/19q co-deletion 
should therefore be offered a combined treatment modality regimen including radio- and 
chemotherapy. PCV, however, is associated with significant hematological toxicity and also 
non-hematological side effects which probably translate into reduced quality of life in long-
term survivors. Therefore, it might be warranted to replace PCV by temozolomide which 
displays a more favorable side effect profile. Data from the NOA-04 study suggest that PCV 
and temozolomide have similar effects. However, long-term data on the benefit from 
temozolomide are lacking making a definite answer on the equivalence of temozolomide and 
PCV in anaplastic oligodendroligoma (AO) impossible. The current evidence precludes RT 
alone for AO patients. Neither the RTOG nor the EORTC trial defined the role of 
chemotherapy alone. A comparison of combined modality treatment with chemotherapy alone 
followed by RT at progression is pending. Long-term follow-up of NOA-04 patients and 
results from future trials may help to clarify these questions. With more and more AO patients 
living 10 years or longer, particular attention must be paid to late side effects such as 
neurotoxicity and careful monitoring is required in all treated patients.  
 
 
Introduction 
 
The group of anaplastic gliomas, also referred to as WHO (World Health Organization) grade 
III tumors, has been histologically subdivided into different subtypes: anaplastic astrocytoma 
(AA), anaplastic oligoastrocytoma (AOA), anaplastic oligodendroglioma (AO) and anaplastic 
ependymoma [1]. Anaplastic oligodendroglial tumors are rare, accounting for less than 5% of 
all primary brain tumors (cbtrus.org). In contrast to WHO grade II tumors, these neoplasms 
display histological features of anaplasia such as nuclear atypia as well as enhanced cellularity 
and increased number of mitotic figures. The MIB1 index as a marker for proliferation is 
typically higher than 5%. The current WHO classification for gliomas lacks the inclusion of 
molecular markers which have gained increasing interest within the last years and have been 
proven to be of prognostic significance [2, 3]. This is of particular interest in anaplastic but 
also WHO grade II gliomas where the inter-observer variability in the subjective 
interpretation of the histopathological findings is still significant [4]. Oligodendroglial tumors 
are characterized by the frequent loss of genetic material from the short arm of chromosome 1 
(1p) and the long arm of chromosome 19 (19q) [5]. This situation, also referred to as 
combined 1p/19q loss or 1p/19q co-deletion, is due to an unbalanced translocation resulting in 
the loss of one hybrid chromosome and loss of heterozygosity (LOH) [6]. How these 
chromosomal aberrations contribute to the pathogenesis of oligodendroglial tumors has not 
yet been clarified, but mutations of different genes including homolog of the Drosophila gene 
capicua (CIC) and far-upstream element (FUSE) binding protein (FUBP1) located on these 
chromosomal fragments may play a critical role [7].  In the absence of radiation therapy or 
alkylating chemotherapy, 1p/19q co-deletion may not be associated with prolonged 
progression-free survival [8] indicating that it is not a prognostic biomarker but rather a 
predictor for favorable responses to radio- or chemotherapy. 
 
 
Treatment 
 
The therapeutic management of AO requires a multidisciplinary approach including surgery, 
irradiation and chemotherapy. The importance of alkylating chemotherapy has recently been 
confirmed by the long-term results of 2 randomized phase III trials. However, it remains a 
matter of debate whether irradiation can be deferred and which alkylating chemotherapy 
regimen is most suitable in terms of efficacy and toxicity. 
 
Surgery 
 
• Even with RT and improved chemotherapeutic options (see below), surgery has 
remained the initial therapeutic procedure. Resection allows for a rapid relief from 
intracranial pressure and neurological symptoms in tumors which are associated with a 
significant mass effect.  
• There is no clear evidence on the beneficial effects of a gross total resection in 
anaplastic oligodendroglial tumors. However, based on the results of several studies 
assessing mainly glioblastoma patients it may be concluded that complete resection is 
also favorable for the outcome with anaplastic gliomas. 5-aminolevulinic acid (5-
ALA) is used for the intraoperative identification and resection of gliomas. Compared 
to conventional microsurgery, 5-ALA-based resection resulted in more complete 
resections of contrast-enhancing tumor which translated into prolonged progression-
free survival [9]. Similarly to many other trials including patients with WHO grade III 
and IV gliomas, the majority of patients treated within this study had a histological 
diagnosis of glioblastoma. Only 3% of the operated tumors were finally diagnosed as 
anaplastic oligodendroglial gliomas. Therefore, the role of 5-ALA for the resection of 
AO remains questionable.  
• Most metaanalyses addressing the effect of surgical resection versus biopsy include 
various histological types of malignant gliomas. Overall, resection may improve the 
quality of life and also increase overall survival [10]. In parallel, surgery-associated 
mortality has decreased most likely due to the availability of advanced intraoperative 
imaging techniques and improved perioperative neuro-anesthesiological care.  
• The extent of resection should be confirmed by an appropriate imaging technique, 
typically MRI, not later than 72 h after the operation. Extent of resection has been 
identified as a prognostic factor in several large clinical trials [11-13]. 
• Because of the increasing importance of molecular markers, the availability of tissue 
specimens is crucial and represents another important aspect of surgery. Patients 
whose tumors are not eligible for complete resection due to the localization in the 
brain or other reasons, need to undergo a biopsy for tissue sampling to allow for 
subsequent histological and molecular profiling. 
 
 
Radiation therapy  
 
• Surgery followed by irradiation was the standard of care of anaplastic 
oligodendroglioma until the early 1990s. Only trials performed during the 1970s 
examined the effect of radiotherapy alone in patients with malignant gliomas. 
Histological glioma specification, however, was mostly lacking at that time resulting 
in a mixture of grade III and IV tumors [14]. 
• Randomized trials enrolling specifically patients with AO looking at the net effect of 
irradiation compared to surgery alone have not been performed and probably will 
never. Still, there is hardly any doubt that radiotherapy is an effective treatment for 
patients with AO. This assumption is stressed by retrospective analyses of patient 
cohorts who had postoperative RT or not reporting that irradiation prolonged survival 
[15]. 
• External beam RT is usually administered in standard fractions of 1.8-2 Gy to a total 
dose in the range of 54 to 60 Gy. There are no data to suggest a beneficial effect of 
doses higher than 60 Gy [16]. Furthermore, whole brain irradiation (WBRT) is not 
more effective than partial brain treatment. Clinical trials looking specifically at 
patients with AO are lacking. In contrast to WBRT, focused radiotherapy may be 
better tolerated and results much less frequently in reduced quality of life [17].  
 
 
Chemotherapy 
 
• For many years there was no consensus on the value of adjuvant chemotherapy in 
patients with anaplastic gliomas. However, it has been recognized more than 25 years 
ago that anaplastic oligodendroglial tumors are markedly more sensitive to 
chemotherapy than most other gliomas [18]. Several smaller, uncontrolled trials within 
the 1990s reported that AO frequently respond to chemotherapy [19]. The most 
commonly administered regimen within these studies included procarbazine, 
lomustine (CCNU) and vincristin (PCV). 
• The observation that anaplastic oligodendroglial tumors respond well to PCV 
chemotherapy resulted in the design of 2 similar trials by the Radiation Therapy 
Oncology Group (RTOG) and the European Organisation for Research and Treatment 
of Cancer (EORTC). Both studies aimed at evaluating the role of PCV chemotherapy 
in combination with radiotherapy compared to radiation therapy alone. The RTOG 
9402 trial randomly assigned 291 patients with AO or anaplastic mixed oligo-
astrocytoma to either RT alone or up to four cycles of PCV chemotherapy with 
subsequent RT [11]. The EORTC 26951 study enrolled 368 patients with pure or 
mixed anaplastic oligodendrogliomas and randomized them to receive either RT alone 
or RT followed by up to six cycles of PCV [12].  
• Initial results of both studies were published in 2006 after a median follow-up period 
of 5 years. Both trials had similar outcomes: (i) patients with 1p/19q co-deletion had a 
longer median survival than patients with non co-deleted tumors. (ii) The progression-
free survival (PFS) time favored the combination of RT and PCV in both studies. (iii) 
The median overall survival (OS) was not different between the RT only and the 
combined modality treatment groups, that is, regardless of whether PCV was given 
before or after RT. (iv) The addition of PCV to irradiation was associated with 
significant, mostly hematological toxicity. 
• Owing to the lack of benefit on overall survival and the considerable toxicity, the 
addition of PCV to RT was not established as a new standard of care. Of note, most of 
the patients who experienced tumor progression after sole irradiation received 
chemotherapy as salvage treatment in both trials. It was believed that this crossover 
effect from chemotherapy that was applied at progression precluded the translation of 
prolonged PFS into a difference in OS.  
• In 2013, long-term follow-up data from both trials were reported [20, 21]. The long-
term results of these 2 trials have now changed the standards of care for patients with 
pure and mixed anaplastic oligodendroglial tumors. In the RTOG study, there was no 
difference in median survival when the entire patient cohort was analyzed. However, 
within the subgroup of patients with co-deleted tumors, PCV plus RT resulted in a 
median survival of 14.7 months vs. 7.3 months for those who had been treated with 
RT alone. No difference in median survival was observed for patients with non co-
deleted tumors. Long-term results of the EORTC trial were obtained after a median 
follow-up of 140 months. In contrast to the RTOG trial, there was a prolonged median 
survival when the whole cohort was assessed, regardless of the 1p/19q status (OS with 
RT/PCV 42.3 months vs. 30.6 months, p=0.18). 80 patients had a 1p/19q co-deletion. 
Here, OS was not yet reached in the RT/PCV group vs. 112 months in the RT group. 
In the subgroup of patients with non co-deleted tumors, no significant difference 
between the RT and RT/PCV arm was observed.  
• Since both trials used different approaches for the sequencing of radio- and 
chemotherapy, both options are valid. Consideration may be given to the influence of 
pre-radiotherapeutic chemotherapy in responding patients on the target volume. But, 
as of now, the target volume will be based on the initial postsurgical MRI.    
• PCV administration results in considerable side effects with hematological toxicity as 
the major limitation. Grade 3 or 4 hematological toxicity was observed in 47% of the 
patients treated within the EORTC trial [12] and in 65% of all patients who were 
enrolled in RTOG 9402 [11]. Only 42% of the patients treated within RTOG 9402 
tolerated all 4 cycles of PCV. Similarly, in EORTC 26951, a median of 3 out of 6 
planned cycles of adjuvant PCV was administered. Only 30% of the patients could 
receive all scheduled 6 PCV cycles. Nevertheless, despite many patients not receiving 
the planned chemotherapeutic regimen, the combined treatment modality arm of the 
study resulted in superior survival as demonstrated by the long-term follow-up.  
• Since 1p/19q co-deletion is more predictive for the clinical course than histology, 2 
large randomized, multicenter trials have been set up for patients with anaplastic 
glioma using the 1p/19q status as inclusion criterion. The CATNON (NCT00626990) 
study has been established for patients with tumors lacking a 1p/19q co-deletion. This 
trial is currently enrolling patients. However, based on the recent findings of RTOG 
9402 and EORTC 26951, the second intergroup study, named CODEL 
(NCT00887146), which had been designed for patients with anaplastic gliomas 
harboring a 1p/19q co-deletion, was put on hold. The trial had been set up with 3 arms 
comparing RT plus concomitant and adjuvant TMZ with RT alone or TMZ alone. 
After publication of the long-term results of the RTOG and EORTC studies, the 
irradiation only arm was no longer regarded appropriate. Whether this trial will be 
continued following design modifications is still a matter of debate. The trial may be 
resumed following a replacement of the RT only arm by a regimen including RT plus 
PCV.  
• A major unresolved question is whether RT can be deferred in favor of chemotherapy 
alone in patients with co-deleted tumors. Whether PCV or temozolomide should be 
used is another matter of debate. Currently, no data from large prospective trials are 
available. Therefore, the results of ongoing and future trials need to be awaited.  
• The use of PCV had been abandoned by many neuro-oncologists within the last 
decade because of its significant, mostly hematological toxicity as outlined above. A 
survey demonstrated that 42% of neuro-oncologists use temozolomide alone in 
patients with AO harboring a co-deletion whereas only 8% use PCV [22]. A similar 
analysis revealed that the PCV regimen was virtually completely replaced by 
temozolomide among patients with AO who received chemotherapy alone or together 
with RT [23].  
• There is also a debate on the role of vincristine within the PCV regimen. Most likely, 
it does not cross the blood-brain barrier and may therefore lack activity against 
gliomas. In contrast, it may exert severe and non-reversible side effects such as 
neuropathies hampering the quality of life of many patients [24-26]. On the other 
hand, we do not know, which drug levels in the contrast-enhancing tumor parts may 
be of benefit for tumor treatment, and the EORTC and RTOG data have been achived 
with PCV and not PC. Temozolomide, when administered concomitantly during RT 
and as adjuvant treatment in patients with newly diagnosed glioblastoma, had only to 
be stopped in 13% of the patients indicating that such a regimen is much better 
tolerable than PCV [27]. Furthermore, in contrast to PCV where vincristine requires 
intravenous application, temozolomide can be administered orally making it a very 
convenient therapeutic option. Temozolomide, when used in AO patients at relapse 
after failure of PCV resulted in considerable response rates and promising survival 
data [28, 29]. More recent studies applied temozolomide alone in patients with newly 
diagnosed AO suggesting similar activity than PCV [30]. In contrast, a retrospective 
analysis assessing the effects of PCV and temozolomide in patients with AO 
demonstrated prolonged survival of patients treated with PCV with a median survival 
of 7.6 years compared to 3.3 years in patients who received temozolomide [31]. 
However, because of the retrospective design of the study, these results may be biased 
by several confounding factors. Overall, there is no similar evidence for the activity of 
temozolomide in AO compared to PCV.   
• The long-term results of the NOA-04 study may partially help to clarify the issue of 
PCV vs. temozolomide chemotherapy as well as the option of deferred RT. The study 
aimed at assessing efficacy and safety of RT or chemotherapy with either PCV or 
temozolomide in patients with anaplastic gliomas. At tumor progression, patients 
within the RT arm were treated with chemotherapy and patients who were initially 
treated with PCV or temozolomide received RT as salvage treatment. The trial 
revealed that both, initial radio- or chemotherapy, resulted in similar median PFS and 
OS [13]. Patients with pure and mixed anaplastic oligodendroglial tumors had 
virtually the same outcome. Prognostic factors confirmed and identified within this 
trial included age, extent of resection, histology, MGMT promoter methylation status 
and IDH1 mutation status. The study also confirmed the much better tolerability of 
temozolomide. Whether first-line chemotherapy alone results in promising OS times 
similar to the combination of RT and PCV in RTOG 9402 and EORTC 26951, will 
only be clarified by a long-term follow up. Since only a minority of patients treated 
within the NOA-04 trial had co-deleted tumors, it must be anticipated that further 
trials are needed for a definitive answer to this question.   
 
 
Other treatments 
 
• Except for surgery, irradiation and chemotherapy using PCV or temozolomide, no 
further treatment modalities have been established in patients with AO. Whenever 
possible, new pharmaceutical agents as well as novel therapeutic approaches such as 
immunotherapy or gene therapy should be assessed within clinical trials.  
• Anti-angiogenic compounds such as the vascular endothelial growth factor (VEGF) 
inhibitor bevacizumab have shown some activity in glioblastoma patients [32]. Several 
smaller studies using bevacizumab alone or in combination with other agents in 
patients with recurrent oligodendroglial tumors suggest that bevacizumab is also 
active in these tumors [33-36]. However, the definite role of bevacizumab and similar 
compounds in the treatment of oligodendroglial tumors – just as for all other grade II 
and III tumors – needs to be defined within the next years. The TAVAREC trial 
(NCT01164189) which is currently enrolling patients with recurrent anaplastic 
gliomas without 1p/19q co-deletion may shed some light on the efficacy of 
bevacizumab in these tumors.  
 
 
Diet and lifestyle 
 
• Currently, there are no data suggesting that diet and lifestyle changes may have any 
impact on the course of disease in AO patients. 
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